Literature DB >> 15660288

Reactive arthritis following BCG immunotherapy for bladder carcinoma.

Elisa Tinazzi1, Vincenzo Ficarra, Sara Simeoni, Dimitri Peterlana, Claudio Lunardi.   

Abstract

Intravesical instillation of bacillus Calmette-Guérin (BCG) is used in the treatment of patients with intermediate and high-risk superficial bladder carcinoma with efficacy and safety. The vast majority of patients do not present any side effects and only 5% of patients have mild and short-lived clinical manifestations such as malaise, low-grade fever, cystitis, and hematuria. Arthralgia and/or arthritis is one of the rare severe complications following intravesical BCG immunotherapy. We report here the case of a patient with reactive arthritis successfully treated with nonsteroidal anti-inflammatory drugs (NSAIDs) after the discontinuation of BCG immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660288     DOI: 10.1007/s10067-004-1063-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  Articular manifestations after the administration of intravesical BCG.

Authors:  Antonio Juan Mas; Montserra Romera; José M Valverde Garcia
Journal:  Joint Bone Spine       Date:  2002-01       Impact factor: 4.929

2.  Two cases of acute polyarthritis secondary to intravesical BCG adjuvant therapy for superficial bladder cancer.

Authors:  N P Pardalidis; A G Papatsoris; E V Kosmaoglou; C Georganas
Journal:  Clin Rheumatol       Date:  2002-11       Impact factor: 2.980

3.  Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27.

Authors:  N Dulphy; M A Peyrat; V Tieng; C Douay; C Rabian; R Tamouza; S Laoussadi; F Berenbaum; A Chabot; M Bonneville; D Charron; A Toubert
Journal:  J Immunol       Date:  1999-04-01       Impact factor: 5.422

4.  T helper 1/2 lymphocyte urinary cytokine profiles in responding and nonresponding patients after 1 and 2 courses of bacillus Calmette-Guerin for superficial bladder cancer.

Authors:  F Saint; J J Patard; P Maille; P Soyeux; A Hoznek; L Salomon; A De La Taille; C C Abbou; D K Chopin
Journal:  J Urol       Date:  2001-12       Impact factor: 7.450

5.  Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.

Authors:  O Onur; R Celiker
Journal:  Clin Rheumatol       Date:  1999       Impact factor: 2.980

Review 6.  Efficacy and safety of bacille Calmette-Guérin immunotherapy in superficial bladder cancer.

Authors:  D L Lamm
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

7.  Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis.

Authors:  Y Shoenfeld; Y Vilner; A R Coates; J Rauch; G Lavie; D Shaul; J Pinkhas
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

8.  Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig.

Authors:  L C De Boer; P A Steerenberg; P M Van der Meijden; B Van Klingeren; W H De Jong; A Elgersma; F M Debruyne; E J Ruitenberg
Journal:  J Urol       Date:  1992-11       Impact factor: 7.450

9.  Common epitopes between mycobacterial and certain host tissue antigens.

Authors:  C J Thorns; J A Morris
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

10.  Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guérin (BCG) immunotherapy.

Authors:  A M Jackson; A B Alexandroff; R W Kelly; A Skibinska; K Esuvaranathan; S Prescott; G D Chisholm; K James
Journal:  Clin Exp Immunol       Date:  1995-03       Impact factor: 4.330

View more
  1 in total

Review 1.  Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review.

Authors:  Elisa Tinazzi; Vincenzo Ficarra; Sara Simeoni; Walter Artibani; Claudio Lunardi
Journal:  Rheumatol Int       Date:  2005-10-12       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.